|Bid||791.62 x 800|
|Ask||825.00 x 800|
|Day's Range||799.77 - 813.28|
|52 Week Range||668.00 - 847.50|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||21.68|
|Earnings Date||Nov 02, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||907.48|
Subscribe to Yahoo Finance Plus to view Fair Value for REGN
Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collabo
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Companies generally decide to engage in stock splits after their shares have soared to a level that may put them out of reach for many retail investors. A stock split doesn't change the real market value of a company, nor does it alter the value of any investor's holdings, but it does bring down the price of each individual share. Of course, it's impossible to predict which company may perform a stock split with 100% accuracy, but a top performer that has been setting new share price highs could make a good candidate.